1155 / 1816
HERA: Overall survival
• No evidence of long-term
benefit of 2 years
compared to 1 year
trastuzumab
• Secondary cardiac
endpoints and other
adverse events are
increased in the 2 years
trastuzumab arm
• The majority of cardiac
endpoints occurred during
trastuzumab
administration and are
reversible